Latest Blogs

May 23, 2023
Whether you participate in person in Chicago, watch sessions online, or keep up with the meeting outcomes and conversations on social media (or any combination of these), I hope the ASCO Annual Meeting leaves you feeling inspired and, above all, connected.
May 04, 2023
"If we can provide chemotherapy services through a tele-chemotherapy model at smaller rural centers, why can’t we do the same for clinical trials?" asks Dr. Sabe Sabesan.
Apr 27, 2023
The ASCO Journals Editorial Fellowship changed Dr. Mona Hassan's perspective on the publication process.
Apr 20, 2023
Novelty socks were the surprising vessel through which Dr. Jon Steinmetz built trust and connection with a withdrawn patient.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a professor emeritus at the University of Colorado Cancer Center. He previously served as chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Disclosure.

Aug 08, 2016
For prostate cancer, there are both challenges and some early positive results from immunotherapy trials that remain intriguing. One of the key challenges is identifying those patients who will benefit from the treatment.
Jun 05, 2016
Much of the news this week in prostate cancer will be generated by the ASCO Annual Meeting in Chicago. There are likely to be considerable news releases regarding precision medicine, and especially AR-V7, so I thought I would explain this a bit.
Feb 16, 2016
In what is the first (and hopefully one of many) example of using modern genomic methods to match treatments to the molecular defects in prostate cancer, the U.S. FDA has just granted “breakthrough designation” to olaparib.
Jan 06, 2016
One of the most frequent questions I hear in my clinic is, “Are we making any progress?” or, “Is there anything new out there?” The answer is always yes, or more properly, YES!
Nov 04, 2015
I think the facet of cancer most commonly misunderstood by non-scientists (patients/families) is heterogeneity. Several presentations at the Prostate Cancer Foundation Annual Retreat touched on this theme.
Aug 05, 2015
Looking back on the 1976 Bonadonna study using CMF chemotherapy in women with breast cancer and positive axillary nodes, I consider what went wrong in the search for similarly effective treatment of prostate cancer.

Pages